EUCTR2013-005586-39-DE进行中（未招募）不适用
A Phase 4 Multicenter, Open-Label, Single Arm Study toEvaluate Switching from BRACET/Gilenya® to Natalizumabin Subjects with Relapsing Forms of Multiple Sclerosis (MS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects of childbearing potential must practice effective contraception from Day -1 and be willing and able to continue contraception for duration of the study.
- •- Must have documented diagnosis of relapsing MS (McDonald 2010 Criteria [Polman 2011]) at Screening.
- •- Must have been treated with Gilenya or BRACET for at least the 12 months prior to Screening with no interruption of treatment greater than 1 month. More than 1 prior disease-modifying therapy is allowed, as long as minimum treatment duration was cumulatively 12 months. Prior treatment with natalizumab is allowed; however, there must be a minimum 1 year since last natalizumab infusion and the Screening visit of this study, and if discontinuation of natalizumab in the past was not due to intolerance, anti-natalizumab antibodies, or efficacy loss.
- •- Must have had disease activity in the 6 months prior to Screening while on Gilenya or BRACET (as defined by at least 1 Gd+ lesion OR at least 2 new T2 lesions (compared with an MRI done within 12 months of screening) OR clinical relapse, or EDSS progression of 1 point)
- •- Must have an EDSS score from 0 to 5.5 inclusive at Screening.
- •NOTE: Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- History or positive test result at Screening for human immunodeficiency virus (HIV). Prior treatment with Tysabri (either commercially or through a clinical study) within 1 year of Day -1.
- •- Contraindications to treatment with Tysabri as described in the Prescribing Information for each of the participating countries.
- •- Known allergy to Tysabri or known to be anti-natalizumab antibody positive.
- •- Diagnosis of primary progressive MS, secondary progressive MS, and/or progressive-relapsing MS.
- •- An MS relapse that has occurred within the 30 days prior to Day -1 and/or the subject has not stabilized from a previous relapse prior to Day -1.
- •- Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
- •- History of severe opportunistic infections (including PML) or any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator
- •- Females breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception; women who have a positive pregnancy test result at Day -1.
- •- Prior history of immunosuppressant use (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab) in the last 12 months prior to Screening. Prior history of alemtuzumab use at any point in the past.
- •NOTE: Other protocol-defined exclusion criteria may apply
研究者
相似试验
已完成
4 期
A clinical trial to describe the safety of 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age.CTRI/2018/11/016324Pfizer Limited Subsidiary of Pfizer Inc100
进行中（未招募）
1 期
A clinical trial that will look at the effect of Apremilast on MRI Outcomes in Patients with Psoriatic ArthritisPsoriatic arthritisEUCTR2018-002748-10-ATAmgen Inc.120
进行中（未招募）
1 期
A clinical trial that will look at the effect of Apremilast on MRI Outcomes in Patients with Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic arthritisEUCTR2018-002748-10-DKAmgen Inc.120
进行中（未招募）
1 期
A clinical trial that will look at the effect of Apremilast on MRI Outcomes in Patients with Psoriatic ArthritisPsoriatic arthritisEUCTR2018-002748-10-DEAmgen Inc.120
进行中（未招募）
1 期
A clinical trial that will look at the effect of Apremilast on MRI Outcomes in Patients with Psoriatic ArthritisMedDRA version: 20.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic arthritisEUCTR2018-002748-10-ESCelgene Corporation123